LightCON Launches NFT Presale for Its New Game, Rise of Stars (ROS)
27.1.2022 07:24:00 EET | Business Wire | Press release
Rise of Stars (ROS), a new mobile game being developed by LightCON, a subsidiary of WEMADE MAX (Co-CEOs: Hyunguk Chang, Gilhyung Lee) (KOSDAQ: 101730), launches NFT presale of Warship Carriers on January 27.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220123005106/en/
Rise of Stars (ROS) launches NFT presale of Warship Carriers on January 27. Warship Carrier is an item providing various buff benefits to the warships and serves as the main axis in the ROS token ecosystem. The presale is held twice between January 27 and February 17 on WEMIX Auction. 1,504 NFT Warship Carrier lucky boxes will be sold at discounted prices on a first-come-first-served basis. (Graphic: Business Wire)
ROS is the first 4x blockchain game to be released on the WEMIX platform. In addition to real-time massive warfare, this game, which is set on the vast universe, features elaborately designed warships and planets.
In particular, ROS provides Silthereum, a new game token, and the item ‘Warship Carrier’ to which NFT is applied. Prior to the official service, the NFT is presold.
Warship Carrier, which carries a large number of warships, is an item providing various buff benefits to the warships and serves as the main axis in the ROS token ecosystem. It offers a function to mine Silther Particles, which are exchanged for Silthereum, the game token. The higher the Warship Carrier tier is, the larger the amount of Silther Particle mining becomes.
The presale is held twice between January 27 and February 17 on WEMIX Auction. 1,504 NFT Warship Carrier lucky boxes will be sold at discounted prices on a first-come-first-served basis.
Through the first presale, 500 Tier-1 Warship Carrier lucky boxes and 252 Tier-2 Warship Carrier lucky boxes will be sold at 20% discounted prices from January 27 to February 3. During the second presale from February 10 to 17, the same amounts will be sold at 10% discounted prices.
To mark the first NFT presale of ROS, 1.2 million Silthereum tokens will be presented through an airdrop event. All NFT buyers will be presented with a total of 201,200 Silthereum tokens. In addition, 20,000 users who participate in the community event will be provided with 50 Silthereum tokens each by lot.
On the 12th, ROS opened the pre-registration on the Google Play and Apple App Store in global regions excluding Korea and China, etc. To celebrate the opening of global pre-registration, an airdrop event offering a total of one million Silthereum tokens is being held.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220123005106/en/
Contact information
For LightCON
Wemade Co., Ltd.
Young Ahn
+82-2-3709-2065
ay2000@wemade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom